US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Actuate Therapeutics Inc

6.59

-0.1500-2.23%

Post-market: 6.55-0.0400-0.61%14:21 EDT

Volume:53.96K

Turnover:347.66K

Market Cap:129.29M

PE:-3.35

High:6.79

Open:6.76

Low:6.28

Close:6.74

Loading ...

Overview Company News Filings

ACTU says Chalmers’ $3m super tax must eventually be indexed

The Australian Financial Review

Bios Equity COF, LP Reports Acquisition of Common Shares of Actuate Therapeutics Inc

Director and 10% Owner Aaron G.L. Fletcher Reports Acquisition of Common Shares of Actuate Therapeutics Inc

Actuate Therapeutics Inc. Announces $4.7 Million Private Placement with Institutional and Accredited Investors

Actuate highlights results from subgroup analysis of Phase 2 elraglusib trial

BRIEF-Actuate Therapeutics Highlights Survival Benefit In Metastatic Pancreatic Cancer Patient Populations

Actuate Therapeutics Inc - Elraglusib Plus Gnp Shows Near Doubling of 1-Year Os

THOMSON REUTERS

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

THOMSON REUTERS

Actuate Therapeutics Identifies Biomarkers in Treatment of Metastatic Pancreatic Cancer in Phase 2 Trial

MT Newswires Live

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data From Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at Asco

THOMSON REUTERS

Actuate Therapeutics announces inclusion in Russell 3000, 2000 indexes

Actuate Therapeutics Hosts Key Opinion Leader Event

Actuate Therapeutics Unveils Phase 2 Topline Data for Elraglusib in Pancreatic Cancer at Key Opinion Leader Event

Actuate Therapeutics shares highlights from KOL eventon elraglusib data

Actuate Therapeutics' Shares Gain on Positive Phase 2 Trial for Pancreatic Cancer Treatment

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at Asco 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

THOMSON REUTERS

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

The 10 occupations targeted by ACTU gender pay blitz

The Australian Financial Review

Actuate Therapeutics Elects Directors at Annual Meeting

Actuate Therapeutics Inc. Held Virtual Annual Stockholders Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACTU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACTU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":6.59,"timestamp":1751561999999,"preClose":6.74,"halted":0,"volume":53961,"hourTrading":{"tag":"盘后","latestPrice":6.55,"preClose":6.59,"latestTime":"14:21 EDT","volume":671,"amount":4397.215317,"timestamp":1751566889188},"delay":0,"floatShares":6049455,"shares":19619660,"eps":-1.967312,"marketStatus":"Post-Mkt","change":-0.15,"latestTime":"07-03 15:02:17 EDT","open":6.76,"high":6.7909,"low":6.2816,"amount":347656.315413,"amplitude":0.075564,"askPrice":7,"askSize":20,"bidPrice":6.31,"bidSize":57,"shortable":3,"etf":0,"ttmEps":-1.967312,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1751576400000},"marketStatusCode":4,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":6.74,"preHourTrading":{"tag":"盘前","latestPrice":6.7604,"preClose":6.74,"latestTime":"08:17 EDT","volume":704,"amount":4764.1135168,"timestamp":1751545034761},"postHourTrading":{"tag":"盘后","latestPrice":6.55,"preClose":6.59,"latestTime":"14:21 EDT","volume":671,"amount":4397.215317,"timestamp":1751566889188},"volumeRatio":0.297244},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","floatShares":6049455,"roa":"-413.43%","roe":"--","lyrEps":-3.258828,"volumeRatio":0.297244,"shares":19619660,"dividePrice":0,"high":6.7909,"amplitude":0.075564,"preClose":6.74,"low":6.2816,"week52Low":5.5,"pbRate":"-25.41","week52High":11.99,"institutionHeld":0,"latestPrice":6.59,"committee":0.480519,"eps":-1.967312,"divideRate":0,"volume":53961,"delay":0,"ttmEps":-1.967312,"open":6.76,"prevYearClose":7.96,"prevWeekClose":5.96,"prevMonthClose":6.11,"prevQuarterClose":6.11,"fiveDayClose":5.82,"twentyDayClose":9.11,"sixtyDayClose":6.82},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACTU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548040009","title":"ACTU says Chalmers’ $3m super tax must eventually be indexed","url":"https://stock-news.laohu8.com/highlight/detail?id=2548040009","media":"The Australian Financial Review","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548040009?lang=en_us&edition=fundamental","pubTime":"2025-07-01 09:45","pubTimestamp":1751334300,"startTime":"0","endTime":"0","summary":"ACTU Secretary Sally McManus says the $3 million threshold above which the government’s new superannuation earnings tax will apply needs to be indexed, but that there is no urgency.A day after compuls","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.afr.com/politics/federal/actu-says-chalmers-super-tax-must-be-indexed-20250701-p5mbiz","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"afr_stock","symbols":["MMM","ACTU","BK4533","SG9999002232.USD","BK4512","SG9999002224.SGD","LU0787776722.HKD","BK4585","LU1093756168.USD","LU1894683264.USD","BK4206","LU1894683348.USD","BK4139","BK4534","LU1093756325.SGD","LU0683600562.USD","BK4588"],"gpt_icon":0},{"id":"2548011572","title":"Bios Equity COF, LP Reports Acquisition of Common Shares of Actuate Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2548011572","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548011572?lang=en_us&edition=fundamental","pubTime":"2025-07-01 01:04","pubTimestamp":1751303079,"startTime":"0","endTime":"0","summary":"Bios Equity COF, LP reported an acquisition of common shares of Actuate Therapeutics Inc. The filing was submitted by more than one reporting person, including Bios Equity COF, LP and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL9s9swQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2548115220","title":"Director and 10% Owner Aaron G.L. Fletcher Reports Acquisition of Common Shares of Actuate Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2548115220","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548115220?lang=en_us&edition=fundamental","pubTime":"2025-07-01 01:02","pubTimestamp":1751302924,"startTime":"0","endTime":"0","summary":"Aaron G.L. Fletcher, a Director and 10% Owner of Actuate Therapeutics Inc., reported the acquisition of common shares of the company. The filing was made by more than one reporting person, including Bios 2024 Co-Invest, LP, among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL3BFL15:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director and 10% Owner Aaron G.L. Fletcher Reports Acquisition of Common Shares of Actuate Therapeutics Inc","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2546172780","title":"Actuate Therapeutics Inc. Announces $4.7 Million Private Placement with Institutional and Accredited Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2546172780","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546172780?lang=en_us&edition=fundamental","pubTime":"2025-06-26 20:12","pubTimestamp":1750939936,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics, Inc. has entered into a securities purchase agreement for a private placement with institutional and accredited investors, expected to close by June 30, 2025. The company anticipates gross proceeds of approximately $4.7 million, which will be used for working capital and general corporate purposes. As part of the agreement, Actuate will issue 666,497 shares of common stock at $7.00 per share and warrants to purchase an equivalent number of shares at the same price. The warrants will be exercisable on a cash-only basis, expiring 20 days after certain FDA-related milestones are reached. Additionally, Actuate has committed to registering the resale of these securities with the SEC, with specific deadlines for filing and effectiveness. Bios 2024 Co-Invest, LP, a significant shareholder, will participate in the private placement, acquiring 71,428 shares and warrants for approximately $500,000.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL8p1fN1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2545238963","title":"Actuate highlights results from subgroup analysis of Phase 2 elraglusib trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2545238963","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545238963?lang=en_us&edition=fundamental","pubTime":"2025-06-24 21:26","pubTimestamp":1750771609,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) highlighted results from a pre-specified subgroup analysis of its Phase 2 trial of elraglusib in combination with gemci...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-highlights-results-from-subgroup-analysis-of-phase-2-elraglusib-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-highlights-results-from-subgroup-analysis-of-phase-2-elraglusib-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2545801012","title":"BRIEF-Actuate Therapeutics Highlights Survival Benefit In Metastatic Pancreatic Cancer Patient Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2545801012","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545801012?lang=en_us&edition=fundamental","pubTime":"2025-06-24 21:17","pubTimestamp":1750771079,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Highlights Survival Benefit In Metastatic Pancreatic Cancer Patient PopulationsJune 24 (Reuters) - Actuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS HIGHLIGHTS SIGNIFICAN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABYFZSF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2545728016","title":"Actuate Therapeutics Inc - Elraglusib Plus Gnp Shows Near Doubling of 1-Year Os","url":"https://stock-news.laohu8.com/highlight/detail?id=2545728016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545728016?lang=en_us&edition=fundamental","pubTime":"2025-06-24 21:15","pubTimestamp":1750770900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABYFZSF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2545280957","title":"Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2545280957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545280957?lang=en_us&edition=fundamental","pubTime":"2025-06-24 21:15","pubTimestamp":1750770900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABYFZSF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2544120502","title":"Actuate Therapeutics Identifies Biomarkers in Treatment of Metastatic Pancreatic Cancer in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2544120502","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544120502?lang=en_us&edition=fundamental","pubTime":"2025-06-20 21:17","pubTimestamp":1750425447,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics  said Friday that its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer demonstrated the use of machine learning and statistical models to predict overall survival based on pre-dose plasma biomarkers.The analysis identified seven biomarkers as \"uniquely significant\" predictors of favorable survival in the elraglusib-treated cohort, the biopharmaceutical company said.The biomarker CXCL2 had an inverse survival trend compared to the gemcitabine/nab-paclitaxel control arm, \"highlighting the potential of elraglusib to favorably affect the immune microenvironment,\" Actuate said.The company said it plans to test the identified biomarkers prospectively in future trials.Shares were 5.8% higher in recent premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","ACTU","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2544273451","title":"Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data From Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at Asco","url":"https://stock-news.laohu8.com/highlight/detail?id=2544273451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544273451?lang=en_us&edition=fundamental","pubTime":"2025-06-20 20:45","pubTimestamp":1750423500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nTUA80MK6R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2543974677","title":"Actuate Therapeutics announces inclusion in Russell 3000, 2000 indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2543974677","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543974677?lang=en_us&edition=fundamental","pubTime":"2025-06-16 20:40","pubTimestamp":1750077638,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced that the Company will be added to the Russell 3000 Index, with automatic inclusion in the Russell 2000( Index...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-inclusion-in-russell-3000-2000-indexes-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-inclusion-in-russell-3000-2000-indexes-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU","BK4539","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2541589003","title":"Actuate Therapeutics Hosts Key Opinion Leader Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2541589003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541589003?lang=en_us&edition=fundamental","pubTime":"2025-06-06 03:17","pubTimestamp":1749151057,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics, Inc. ( ($ACTU) ) just unveiled an announcement. On May 31, 2025, Actuate Therapeutics hosted a Key Opinion Leader event to di...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-hosts-key-opinion-leader-event?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-hosts-key-opinion-leader-event?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACTU","BK4539","BK4007","LENZ"],"gpt_icon":0},{"id":"2541008402","title":"Actuate Therapeutics Unveils Phase 2 Topline Data for Elraglusib in Pancreatic Cancer at Key Opinion Leader Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2541008402","media":"Reuters","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541008402?lang=en_us&edition=fundamental","pubTime":"2025-06-06 02:58","pubTimestamp":1749149923,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL23X3CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2540379306","title":"Actuate Therapeutics shares highlights from KOL eventon elraglusib data","url":"https://stock-news.laohu8.com/highlight/detail?id=2540379306","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540379306?lang=en_us&edition=fundamental","pubTime":"2025-06-02 21:15","pubTimestamp":1748870132,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced key takeaways from its Key Opinion Leader event held on May 31, 2025 discussing the topline results from the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-shares-highlights-from-kol-eventon-elraglusib-data-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-shares-highlights-from-kol-eventon-elraglusib-data-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ACTU","BK4539","BK4139","BK4007","KOL"],"gpt_icon":0},{"id":"2540762387","title":"Actuate Therapeutics' Shares Gain on Positive Phase 2 Trial for Pancreatic Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540762387","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540762387?lang=en_us&edition=fundamental","pubTime":"2025-06-02 18:34","pubTimestamp":1748860440,"startTime":"0","endTime":"0","summary":"Shares of Actuate Therapeutics climbed after data from a recent trial of the company's in-development pancreatic cancer treatment showed that the drug improved overall survival.The stock rose 15% to $13.63, in pre-market trading Monday. Its shares, which began publicly trading last August, hit a high of $11.99 on Friday and are up 50% so far this year.The clinical-stage biopharmaceutical company said its phase 2 study of the drug, elraglusib, met its primary endpoint of improved median overall survival. Median overall survival increased by almost three months, with a 37% reduction in the risk of death and strong statistical significance.These results represent a clinically meaningful advance in the potential treatment of metastatic pancreatic ductal adenocarcinoma, an aggressive form of pancreatic cancer in which the tumor has spread to other parts of the body, the company said.\"Based on the clear clinical benefit and well-tolerated safety profile, we intend to engage with the FDA and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ACTU","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2540782673","title":"Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at Asco 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2540782673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540782673?lang=en_us&edition=fundamental","pubTime":"2025-06-01 04:30","pubTimestamp":1748723402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nTUA9MBDLS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2540675793","title":"Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2540675793","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540675793?lang=en_us&edition=fundamental","pubTime":"2025-06-01 04:30","pubTimestamp":1748723400,"startTime":"0","endTime":"0","summary":"Phase 2  trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival  in previously untreated patients with metastatic pancreatic ductal adenocarcinoma  receiving elraglusib/GnP. Risk of death was reduced by 37%  in patients treated with elraglusib/GnP. Data featured as an oral presentation at the ASCO Annual Meeting. Company plans to engage with FDA in the second half of 2025 to align on a path towards product registration. The trial met its primary endpoint of improved median overall survival. Median overall survival  increased by almost three months  with a 37% reduction in the risk of death and strong statistical significance, representing a clinically meaningful advance in the potential treatment of mPDAC. Patients receiving elraglusib with GnP achieved a 12-month survival rate in 44.1% of patients treated—double that of GnP alone .Daniel Schmitt, President & Chief Executive Officer of Actuate added, “We significantly improved mOS, cut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actuate-therapeutics-presents-topline-elraglusib-203000713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","LENZ","BK4007","ACTU"],"gpt_icon":0},{"id":"2538114412","title":"The 10 occupations targeted by ACTU gender pay blitz","url":"https://stock-news.laohu8.com/highlight/detail?id=2538114412","media":"The Australian Financial Review","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538114412?lang=en_us&edition=fundamental","pubTime":"2025-05-25 16:41","pubTimestamp":1748162460,"startTime":"0","endTime":"0","summary":"Unions are lining up hundreds of thousands of workers for the next wave of gender pay increases, from retail staff and hairdressers to legal conveyancers and receptionists.The ACTU has asked the Fair Work Commission’s minimum wage panel to prioritise 10 occupations for pay reviews in its decision next month and has flagged several more in the coming years, covering about 350,000 workers.Loading...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.afr.com/work-and-careers/workplace/gender-pay-wave-to-hit-business-actu-moves-on-priority-list-20250525-p5m1z8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"afr_stock","symbols":["ACTU"],"gpt_icon":0},{"id":"2537815221","title":"Actuate Therapeutics Elects Directors at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2537815221","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537815221?lang=en_us&edition=fundamental","pubTime":"2025-05-24 04:32","pubTimestamp":1748032356,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics, Inc. ( ($ACTU) ) just unveiled an update. On May 22, 2025, Actuate Therapeutics, Inc. held its Annual Meeting of Stockholders...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-elects-directors-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-elects-directors-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ACTU","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2537755154","title":"Actuate Therapeutics Inc. Held Virtual Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2537755154","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537755154?lang=en_us&edition=fundamental","pubTime":"2025-05-24 04:11","pubTimestamp":1748031070,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics, Inc. held its Annual Meeting of Stockholders virtually on May 22, 2025. During the meeting, stockholders elected Dr. Roger Sawhney, Mr. Todd Thomson, and Dr. Dan Zabrowski to the Board of Directors. Additionally, the appointment of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Both proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 23, 2025, and is solely responsible for the information contain","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL2HFMst:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACTU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"ACTU","fiscalQuarterEnding":"2025/03","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACTU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACTU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1745380800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACTU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACTU","date":"2025-07-02","current":-4.752514,"percent":0.933921,"low":-9.225925,"twenty":-6.395005,"median":-5.691218,"eighty":-5.04517,"high":-3.930949,"avg":-5.821694,"sd":0.891853,"marketCap":120268515},"quantilePoints":[{"date":"2024-07-25","current":-6.211408,"twenty":-6.211408,"median":-6.211408,"eighty":-6.211408,"marketCap":172493433},{"date":"2024-08-09","current":-5.505609,"twenty":-6.211408,"median":-6.211408,"eighty":-6.070248,"marketCap":152893088},{"date":"2024-08-16","current":-5.987349,"twenty":-6.211408,"median":-6.167236,"eighty":-5.841451,"marketCap":166271233},{"date":"2024-08-23","current":-5.560665,"twenty":-6.211408,"median":-5.987349,"eighty":-5.556536,"marketCap":154422018},{"date":"2024-08-30","current":-5.540019,"twenty":-6.211408,"median":-5.870355,"eighty":-5.533137,"marketCap":153848669},{"date":"2024-09-06","current":-5.608839,"twenty":-6.158401,"median":-5.624324,"eighty":-5.529008,"marketCap":155759833},{"date":"2024-09-13","current":-5.512491,"twenty":-6.078798,"median":-5.608839,"eighty":-5.512491,"marketCap":153084204},{"date":"2024-09-20","current":-5.03075,"twenty":-6.012125,"median":-5.608839,"eighty":-5.509738,"marketCap":139706059},{"date":"2024-09-27","current":-4.249491,"twenty":-5.950186,"median":-5.560665,"eighty":-5.486339,"marketCap":122463357},{"date":"2024-10-04","current":-5.056014,"twenty":-5.921282,"median":-5.540019,"eighty":-5.041842,"marketCap":145706004},{"date":"2024-10-11","current":-4.981461,"twenty":-5.86072,"median":-5.519373,"eighty":-4.824223,"marketCap":143557524},{"date":"2024-10-18","current":-4.920464,"twenty":-5.785018,"median":-5.512491,"eighty":-4.844556,"marketCap":141799677},{"date":"2024-10-25","current":-5.774428,"twenty":-5.765917,"median":-5.512491,"eighty":-4.844556,"marketCap":166409538},{"date":"2024-11-01","current":-5.306781,"twenty":-5.809795,"median":-5.512491,"eighty":-4.893354,"marketCap":152932709},{"date":"2024-11-08","current":-5.937088,"twenty":-5.927371,"median":-5.540019,"eighty":-4.957062,"marketCap":171097131},{"date":"2024-11-15","current":-5.958745,"twenty":-5.939799,"median":-5.550342,"eighty":-5.011034,"marketCap":169534600},{"date":"2024-11-22","current":-6.164693,"twenty":-5.973458,"median":-5.595075,"eighty":-5.037775,"marketCap":175394091},{"date":"2024-11-29","current":-5.581175,"twenty":-6.024512,"median":-5.608839,"eighty":-5.04517,"marketCap":158792200},{"date":"2024-12-06","current":-6.144098,"twenty":-6.055165,"median":-5.638088,"eighty":-5.051947,"marketCap":174808142},{"date":"2024-12-13","current":-5.917556,"twenty":-6.037784,"median":-5.643249,"eighty":-5.107523,"marketCap":168362702},{"date":"2024-12-20","current":-4.647547,"twenty":-6.017783,"median":-5.638088,"eighty":-5.04517,"marketCap":132229175},{"date":"2024-12-27","current":-6.068584,"twenty":-6.019156,"median":-5.638088,"eighty":-5.043814,"marketCap":172659662},{"date":"2025-01-03","current":-5.718473,"twenty":-6.013664,"median":-5.622603,"eighty":-5.049236,"marketCap":162698527},{"date":"2025-01-10","current":-5.697878,"twenty":-5.992612,"median":-5.622603,"eighty":-5.054658,"marketCap":162112578},{"date":"2025-01-17","current":-5.917556,"twenty":-5.969958,"median":-5.636367,"eighty":-5.146627,"marketCap":168362702},{"date":"2025-01-24","current":-6.940428,"twenty":-6.032033,"median":-5.643249,"eighty":-5.178584,"marketCap":197464839},{"date":"2025-01-31","current":-6.199017,"twenty":-6.064465,"median":-5.677284,"eighty":-5.209185,"marketCap":176370673},{"date":"2025-02-07","current":-6.047989,"twenty":-6.091559,"median":-5.691423,"eighty":-5.241176,"marketCap":172073713},{"date":"2025-02-14","current":-5.327173,"twenty":-6.072917,"median":-5.687582,"eighty":-5.255778,"marketCap":151565495},{"date":"2025-02-21","current":-5.279119,"twenty":-6.065838,"median":-5.658037,"eighty":-5.254405,"marketCap":150198280},{"date":"2025-02-28","current":-4.970198,"twenty":-6.060665,"median":-5.639808,"eighty":-5.174772,"marketCap":141409044},{"date":"2025-03-07","current":-4.771115,"twenty":-6.057666,"median":-5.608839,"eighty":-5.040292,"marketCap":135744870},{"date":"2025-03-14","current":-5.189762,"twenty":-6.053039,"median":-5.581175,"eighty":-5.033989,"marketCap":141604361},{"date":"2025-03-21","current":-4.831847,"twenty":-6.048768,"median":-5.560665,"eighty":-5.014488,"marketCap":131838543},{"date":"2025-03-28","current":-5.655051,"twenty":-6.042497,"median":-5.560665,"eighty":-5.033989,"marketCap":154299924},{"date":"2025-04-04","current":-4.932064,"twenty":-6.028767,"median":-5.540019,"eighty":-4.987939,"marketCap":134572972},{"date":"2025-04-11","current":-5.483252,"twenty":-6.017783,"median":-5.519391,"eighty":-4.984609,"marketCap":149612331},{"date":"2025-04-17","current":-5.726634,"twenty":-6.012291,"median":-5.540019,"eighty":-4.990995,"marketCap":156253088},{"date":"2025-04-25","current":-6.406672,"twenty":-6.045243,"median":-5.553757,"eighty":-4.998855,"marketCap":174808142},{"date":"2025-05-02","current":-7.537682,"twenty":-6.061192,"median":-5.567445,"eighty":-5.009067,"marketCap":205668127},{"date":"2025-05-09","current":-7.408833,"twenty":-6.107591,"median":-5.601957,"eighty":-5.032369,"marketCap":202152432},{"date":"2025-05-16","current":-8.179286,"twenty":-6.139979,"median":-5.636367,"eighty":-5.039569,"marketCap":206987413},{"date":"2025-05-23","current":-7.830407,"twenty":-6.178422,"median":-5.644452,"eighty":-5.043814,"marketCap":198158566},{"date":"2025-05-30","current":-8.194792,"twenty":-6.211408,"median":-5.662735,"eighty":-5.049236,"marketCap":207379806},{"date":"2025-06-06","current":-7.047366,"twenty":-6.281396,"median":-5.690843,"eighty":-5.056014,"marketCap":178342709},{"date":"2025-06-13","current":-6.675228,"twenty":-6.406672,"median":-5.69465,"eighty":-5.089546,"marketCap":168925272},{"date":"2025-06-20","current":-5.806906,"twenty":-6.42894,"median":-5.722554,"eighty":-5.141086,"marketCap":146951253},{"date":"2025-06-27","current":-4.512175,"twenty":-6.410449,"median":-5.697878,"eighty":-5.08284,"marketCap":114186421},{"date":"2025-07-02","current":-4.752514,"twenty":-6.395005,"median":-5.691218,"eighty":-5.04517,"marketCap":120268515}],"updateTime":1751546210962}}}